Literature DB >> 11389256

Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn.

M Ellington1, D O'Reilly, E N Allred, M C McCormick, D L Wessel, S Kourembanas.   

Abstract

OBJECTIVE: To describe health and neurodevelopmental outcomes and parental satisfaction with hospital care among surviving intervention and control enrollees in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn (PPHN).
METHODS: All surviving enrollees 1 to 4 years of age were eligible for follow-up. Outcomes were assessed by telephone using a trained interviewer and standardized instruments. Domains assessed included parental report of specific conditions and hospital use, rating of general health, cognitive and motor development, behavior problems, temperament, and satisfaction with the hospital stay. Fisher's exact test and the Wilcoxon rank sum test assessed differences between intervention and control infants.
RESULTS: Interviews were completed on 60 of 83 survivors (72%). Eighteen families (22%) could not be located, 2 (2%) were non-English-speaking, and 3 (4%) declined participation. No postdischarge deaths were ascertained. Among those interviewed, race, income, and education of parents of intervention and controls were comparable, as were entry oxygenation index, extracorporeal oxygenation utilization, and days of hospitalization. No differences were found in pulmonary, neurologic, cognitive, behavioral, or neurosensory outcomes; hospital readmission rates; or parental ratings of child's health. The overall neurologic handicap rate was 15%. The rate of hearing deficit was 7%. The rate of significant behavioral problems was 26%. Levels of satisfaction expressed were high for each group. No differences in parental ratings were found between the 2 groups.
CONCLUSIONS: No adverse health or neurodevelopmental outcomes have been observed among infants treated with nitric oxide for PPHN. The parents of the critically ill infants enrolled in our clinical trial welcomed their child's inclusion and all expressed satisfaction with the care that their child received while at a tertiary care hospital. Enrollment in either arm of this randomized, controlled trial did not seem to affect parental satisfaction with the hospital care that their child received.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389256     DOI: 10.1542/peds.107.6.1351

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Nitric oxide for respiratory failure in infants born at or near term.

Authors:  Keith J Barrington; Neil Finer; Thomas Pennaforte; Gabriel Altit
Journal:  Cochrane Database Syst Rev       Date:  2017-01-05

2.  Neurodevelopmental outcome of newborns with persistent pulmonary hypertension.

Authors:  Jaafar Rohana; Nem Yun Boo; Viji Chandran; Rajini Sarvananthan
Journal:  Malays J Med Sci       Date:  2011-10

3.  High prevalence of minor neurologic deficits in a long-term neurodevelopmental follow-up of children with severe persistent pulmonary hypertension of the newborn: a cohort study.

Authors:  Anna Berti; Augusta Janes; Riccardo Furlan; Francesco Macagno
Journal:  Ital J Pediatr       Date:  2010-06-13       Impact factor: 2.638

4.  Patient characteristics in persistent pulmonary hypertension of the newborn.

Authors:  M T R Roofthooft; A Elema; K A Bergman; R M F Berger
Journal:  Pulm Med       Date:  2011-05-24

5.  Inhaled nitric oxide applications in paediatric practice.

Authors:  A Bernasconi; M Beghetti
Journal:  Images Paediatr Cardiol       Date:  2002-01

6.  Development of a Plain Language Decision Support Tool for Cancer Clinical Trials: Blending Health Literacy, Academic Research, and Minority Patient Perspectives.

Authors:  Aisha T Langford; Sarah T Hawley; Sue Stableford; Jamie L Studts; Margaret M Byrne
Journal:  J Cancer Educ       Date:  2020-06       Impact factor: 1.771

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.